4D Molecular (FDMT) Therapeutics announced a strategically focused pipeline, updated Phase 3 4FRONT program plans, initial 4FRONT guidance and resulting updated cash runway guidance. Strategically focused pipeline optimizes resource allocation to progress two product candidates with strongest clinical proof of concept: 4D-150 for wet AMD and DME and 4D-710 for cystic fibrosis. After alignment with FDA and EMA on trial designs for the 4D-150 Phase 3 4FRONT program in wet AMD, 4FRONT-1 and 4FRONT-2 trials on track to initiate in Q1 2025 and Q3 2025 respectively. Primary endpoint 52-week topline data for both 4FRONT-1 and 4FRONT-2 expected in H2 2027. Cash runway extended under updated operating plan; unaudited cash, cash equivalents and marketable securities of $506M as of December 31, 2024 expected to fund operations into 2028.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on FDMT:
- 4D Molecular announces interim data on 4D-150 SPECTRA clincial trial
- 4D Molecular price target lowered to $46 from $79 at BofA
- 4D Molecular announces publication of 4D-150 preclinical data
- 4D Molecular initiated with an Underweight at Morgan Stanley
- 4D Molecular Therapeutics’ Positive Q3 and Strategic Advances